|
Q4 2024
|
28 |
2,874,091 |
NUVL, ACLX, ARGX, RVMD
|
13F-HR
|
2/14/2025 |
000185565525000004 |
|
Q3 2024
|
33 |
2,955,926 |
NUVL, ACLX, ARGX, RVMD
|
13F-HR
|
11/14/2024 |
000185565524000014 |
|
Q2 2024
|
35 |
2,613,016 |
NUVL, ARGX, ACLX, RVMD
|
13F-HR
|
8/14/2024 |
000185565524000009 |
|
Q1 2024
|
34 |
2,840,751 |
NUVL, ACLX, ARGX, IRON
|
13F-HR
|
5/15/2024 |
000185565524000005 |
|
Q4 2023
|
30 |
2,135,928 |
NUVL, ACLX, ARGX, IRON
|
13F-HR
|
2/14/2024 |
000185565524000002 |
|
Q3 2023
|
31 |
1,473,652 |
LEGN, ARGX, ACLX, OLMA
|
13F-HR
|
11/14/2023 |
000185565523000011 |
|
Q2 2023
|
30 |
1,294,170 |
LEGN, INCY, IMCR, ACLX
|
13F-HR
|
8/14/2023 |
000185565523000008 |
|
Q1 2023
|
25 |
1,055,174 |
BIIB, INCY, LEGN, ARGX
|
13F-HR
|
5/15/2023 |
000185565523000006 |
|
Q4 2022
|
23 |
851,901 |
INCY, BIIB, MRTX, HZNP
|
13F-HR
|
2/14/2023 |
000185565523000003 |
|
Q3 2022
|
28 |
750,139 |
GLOBAL BLOOD THERAPEUTICS IN, MRTX, INCY, ASND
|
13F-HR
|
11/14/2022 |
000185565522000011 |
|
Q2 2022
|
23 |
501,530 |
LEGN, GLOBAL BLOOD THERAPEUTICS IN, MRTX, SRRA
|
13F-HR
|
8/15/2022 |
000185565522000008 |
|
Q1 2022
|
25 |
378,175 |
ASND, GLOBAL BLOOD THERAPEUTICS IN, ARVN, LEGN
|
13F-HR
|
5/16/2022 |
000185565522000006 |
|
Q4 2021
|
24 |
350,154 |
MRTX, ASND, ZNTL, VRDN
|
13F-HR
|
2/14/2022 |
000185565522000004 |